临床试验/NCT00169546

NCT00169546已完成4 期

Randomised, Double-blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS ® Inhlaer 50/100mcg Twice Daily vs. FLIXOTIDE® Inhaler 200mcg Twice Daily.

GlaxoSmithKline1 个研究点分布在 1 个国家目标入组 64 人开始时间: 2003年1月最近更新: 2016年9月15日

适应症

干预措施

试验速览

阶段: 4 期
状态: 已完成
发起方: GlaxoSmithKline
入组人数: 64
试验地点: 1
主要终点: sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Comparison of two asthma treatments by lung function measures.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 4 Years 至 11 Years（Child）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

•3 or more courses of oral steroids in last 12 months.

研究组 & 干预措施

Arm 1

Experimental

干预措施: Salmeterol/fluticasone propionate (Drug)

Arm 1

Experimental

干预措施: Fluticasone propionate (Drug)

结局指标

主要结局

sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)

次要结局

sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.

研究者

发起方

GlaxoSmithKline

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

4 期

Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.Asthma

NCT00370591GlaxoSmithKline48

已完成

3 期

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaAsthma

NCT06502366AstraZeneca424

已完成

4 期

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®Chronic Obstructive Pulmonary Disease (COPD)

NCT00542880AstraZeneca442

已完成

3 期

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthma

NCT00393952SkyePharma AG557

已完成

3 期

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With AsthmaAsthma

NCT00393991SkyePharma AG475